Security
Aclaris Therapeutics, Inc. Common Stock · ACRS
ACRSNASDAQCommon stockCurrentCIK 1557746Updated Oct 28, 2026
ACRS price & chart
Loading TradingView…
NASDAQ:ACRS on TradingView ↗About the company
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn.
In the news
No coverage from other publishers is available.
Recent filings
Entry into a Material Definitive Agreement
Items 1.01, 9.01
424B5 filing
Results of Operations and Financial Condition · Regulation FD Disclosure · Other Events
Items 2.02, 7.01, 8.01, 9.01
Entry into a Material Definitive Agreement
Items 1.01, 9.01
S-3ASR filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 175,534,000Source | 182,394,000Source | 179,693,000Source | 189,147,000Source | 161,071,000Source | 198,720,000Source | 198,094,000Source | 174,065,000Source | 160,460,000Source | 220,327,000Source | 197,405,000Source | 254,596,000Source |
| Property, Plant and Equipment, NetUSD | 811,000Source | 1,133,000Source | 664,000Source | 868,000Source | 1,293,000Source | 750,000Source | 942,000Source | 1,531,000Source | 761,000Source | 1,008,000Source | 1,620,000Source | 1,099,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | — | — | 269,000Source | 6,973,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 25,256,000Source | 47,651,000Source | 19,167,000Source | 25,402,000Source | 22,834,000Source | 28,660,000Source | 30,357,000Source | 35,841,000Source | 19,960,000Source | 24,570,000Source | 39,878,000Source | 45,277,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | 343,000Source | — | 194,000Source | 325,000Source | — | 250,000Source | 373,000Source | — | 318,000Source | 298,000Source | 484,000Source |
| Assets, CurrentUSD | 100,592,000Source | 132,330,000Source | 97,765,000Source | 104,202,000Source | 117,635,000Source | 110,230,000Source | 108,790,000Source | 135,338,000Source | 96,316,000Source | 125,951,000Source | 128,856,000Source | 231,550,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | — | 4,265,000Source | — | 4,202,000Source | 6,217,000Source | — | 3,226,000Source | 6,799,000Source | — | 12,039,000Source | 9,452,000Source | 13,495,000Source |
| Other Assets, NoncurrentUSD | 2,834,000Source | 3,217,000Source | 2,199,000Source | 2,993,000Source | 3,365,000Source | 2,368,000Source | 3,151,000Source | 3,997,000Source | 2,771,000Source | 3,066,000Source | 3,889,000Source | 2,732,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 55,434,000Source | 52,243,000Source | 55,112,000Source | 57,408,000Source | 27,249,000Source | 55,071,000Source | 54,028,000Source | 32,051,000Source | 57,378,000Source | 64,773,000Source | 40,226,000Source | 56,975,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 1,000Source | 1,000Source | 1,000Source | 1,000Source | 1,000Source | 1,000Source | 1,000Source | 1,000Source | 1,000Source | 1,000Source | 1,000Source | 1,000Source |
| Additional Paid in CapitalUSD | 1,067,491,000Source | 936,032,000Source | 1,133,997,000Source | 1,064,631,000Source | 933,007,000Source | 1,131,234,000Source | 1,061,577,000Source | 930,114,000Source | 1,070,255,000Source | 1,058,317,000Source | 928,080,000Source | 880,832,000Source |
| Retained Earnings (Accumulated Deficit)USD | -947,989,000Source | -806,309,000Source | -1,009,113,000Source | -933,375,000Source | -798,723,000Source | -987,608,000Source | -917,946,000Source | -787,737,000Source | -967,784,000Source | -902,861,000Source | -770,796,000Source | -682,315,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 597,000Source | 427,000Source | -304,000Source | 482,000Source | -463,000Source | 22,000Source | 434,000Source | -364,000Source | 610,000Source | 97,000Source | -106,000Source | -897,000Source |
| Stockholders' Equity Attributable to ParentUSD | 120,100,000Source | 130,151,000Source | 124,581,000Source | 131,739,000Source | 133,822,000Source | 143,649,000Source | 144,066,000Source | 142,014,000Source | 103,082,000Source | 155,554,000Source | 157,179,000Source | 197,621,000Source |
| Liabilities and EquityUSD | 175,534,000Source | 182,394,000Source | 179,693,000Source | 189,147,000Source | 161,071,000Source | 198,720,000Source | 198,094,000Source | 174,065,000Source | 160,460,000Source | 220,327,000Source | 197,405,000Source | 254,596,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 25,631,000Source | 18,816,000Source | 28,241,000Source | 26,839,000Source | 15,682,000Source | 27,370,000Source | 21,514,000Source | 20,080,000Source | 28,645,000Source | 31,596,000Source | 30,952,000Source | 21,938,000Source |
| Operating Lease, Liability, CurrentUSD | 533,000Source | 465,000Source | 588,000Source | 515,000Source | 449,000Source | 569,000Source | 498,000Source | 503,000Source | 551,000Source | 481,000Source | 426,000Source | 684,000Source |
| Accounts Payable, CurrentUSD | 9,187,000Source | 7,662,000Source | 15,516,000Source | 8,797,000Source | 7,269,000Source | 14,731,000Source | 6,354,000Source | 10,810,000Source | 13,158,000Source | 4,690,000Source | 8,878,000Source | 10,351,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,711,000Source | 2,245,000Source | 1,262,000Source | 1,851,000Source | 2,367,000Source | 1,416,000Source | 1,986,000Source | 2,971,000Source | 1,565,000Source | 2,117,000Source | 3,074,000Source | 1,570,000Source |
| Deferred Income Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | — | — | — | 367,000Source |
| Other Liabilities, NoncurrentUSD | 1,711,000Source | 2,245,000Source | 1,262,000Source | 1,851,000Source | 2,367,000Source | 1,416,000Source | 4,308,000Source | 2,971,000Source | 1,565,000Source | 4,439,000Source | 3,074,000Source | 1,570,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 9,784,000Source | 4,722,000Source | 5,959,000Source | 11,411,000Source | 5,762,000Source | 5,896,000Source | 8,572,000Source | 6,565,000Source | 8,791,000Source | 20,333,000Source | 19,446,000Source | 8,701,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 167,200,000Source | 173,400,000Source | 170,600,000Source | 180,900,000Source | 149,900,000Source | 190,800,000Source | 190,500,000Source | 161,400,000Source | 151,400,000Source | 203,900,000Source | 181,900,000Source | 229,800,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 0Source | — | — | 367,000Source |
| Dividends PayableUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -19,824,000Source | -15,085,000Source | -64,923,000Source | -132,065,000Source | -88,481,000Source | -86,908,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 102,000Source | 128,000Source | 454,000Source | 807,000Source | 863,000Source | 797,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 3,198,000Source | 3,535,000Source | 12,384,000Source | 10,856,000Source | 20,542,000Source | 15,039,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | — | -68,000Source | — | 20,000Source | -186,000Source | -139,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 1,513,000Source | 1,664,000Source | 8,447,000Source | -4,188,000Source | -1,473,000Source | 368,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -18,149,000Source | -13,057,000Source | -47,113,000Source | -20,075,000Source | -78,325,000Source | -67,567,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -30,932,000Source | 19,119,000Source | 48,365,000Source | -69,769,000Source | 46,220,000Source | 12,628,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 13,000Source | 43,000Source | 111,000Source | 121,000Source | 1,309,000Source | 605,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 250,000Source | 275,000Source | 446,000Source | 409,000Source | 102,000Source | 34,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 57,781,000Source | -275,000Source | -5,862,000Source | 74,536,000Source | 26,706,000Source | 72,867,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 8,700,000Source | 5,787,000Source | -4,610,000Source | -15,308,000Source | -5,399,000Source | 17,928,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 25,256,000Source | 47,651,000Source | 19,167,000Source | 25,402,000Source | 28,660,000Source | 30,357,000Source | 19,960,000Source | 24,570,000Source | 39,878,000Source | 45,277,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 2,860,000Source | 3,004,000Source | 2,672,000Source | 3,063,000Source | 3,198,000Source | 3,535,000Source | 12,384,000Source | 10,856,000Source | 20,542,000Source | 15,039,000Source |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | — | — | 75,000Source | 75,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 167,200,000Source | 173,400,000Source | 170,600,000Source | 180,900,000Source | 190,800,000Source | 190,500,000Source | 151,400,000Source | 203,900,000Source | 181,900,000Source | 229,800,000Source |
| DepreciationUSD | — | — | 100,000Source | 200,000Source | — | 100,000Source | — | 100,000Source | — | 700,000Source | 800,000Source | 700,000Source |
| Dividends PayableUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | — |
| General and Administrative ExpenseUSD | — | — | 4,871,000Source | 5,653,000Source | 6,048,000Source | 5,386,000Source | 6,743,000Source | 6,139,000Source | 21,972,000Source | 22,203,000Source | 32,412,000Source | 25,133,000Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | — | — | 6,629,000Source | — |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | — | — | — | — | — | — | — | — | — | -86,908,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | — | -367,000Source | — |
| Investment Income, InterestUSD | — | — | 1,819,000Source | 1,991,000Source | 1,761,000Source | 2,018,000Source | 1,514,000Source | 2,166,000Source | 7,637,000Source | 7,953,000Source | — | — |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | 115,000Source | 890,000Source | -326,000Source | 48,000Source | -588,000Source | 337,000Source | 513,000Source | 203,000Source | 791,000Source | -673,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -14,614,000Source | -7,586,000Source | -21,505,000Source | -15,429,000Source | -19,824,000Source | -15,085,000Source | -64,923,000Source | -132,065,000Source | -88,481,000Source | -86,908,000Source |
| Nonoperating Income (Expense)USD | — | — | 2,535,000Source | 2,885,000Source | 2,733,000Source | 2,979,000Source | 2,368,000Source | 2,999,000Source | 11,452,000Source | 9,867,000Source | — | — |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | 800,000Source | 900,000Source | 1,100,000Source | 1,000,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | — | — | 8,509,000Source | 2,946,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 151,000Source | — | — | 32,000Source | 94,000Source | 157,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 3,299,000Source | 4,346,000Source | 1,629,000Source | 1,777,000Source | 1,996,000Source | 1,455,000Source | 7,826,000Source | 18,720,000Source | 31,249,000Source | 29,752,000Source |
| Cost of Goods and Services Sold | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Gross Profit (Calculated) · Derived | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Income (Loss)USD | — | — | -17,149,000Source | -10,471,000Source | -24,238,000Source | -18,408,000Source | -22,192,000Source | -18,084,000Source | -76,375,000Source | -141,932,000Source | -97,357,000Source | -89,854,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | — | — | 8,509,000Source | 2,946,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -14,614,000Source | -7,586,000Source | — | -15,429,000Source | — | -15,085,000Source | -64,923,000Source | -132,065,000Source | -88,848,000Source | -86,908,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | — | -367,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -14,614,000Source | -7,586,000Source | -21,505,000Source | -15,429,000Source | -19,824,000Source | -15,085,000Source | -64,923,000Source | -132,065,000Source | -88,481,000Source | -86,908,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.12Source | -0.11Source | -0.15Source | -0.13Source | -0.15Source | -0.12Source | -0.53Source | -1.71Source | -1.27Source | -1.33Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.12Source | -0.11Source | -0.15Source | -0.13Source | -0.15Source | -0.12Source | -0.53Source | -1.71Source | -1.27Source | -1.33Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 122,619,311Source | 71,381,731Source | 142,736,848Source | 122,580,967Source | 128,810,050Source | 122,390,303Source | 122,564,741Source | 77,296,665Source | 69,808,855Source | 65,213,944Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 122,619,311Source | 71,381,731Source | 142,736,848Source | 122,580,967Source | 128,810,050Source | 122,390,303Source | 122,564,741Source | 77,296,665Source | 69,808,855Source | 65,213,944Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | — | — | 75,000Source | 75,000Source |
| Costs and ExpensesUSD | — | — | 20,448,000Source | 14,817,000Source | 25,867,000Source | 20,185,000Source | 24,188,000Source | 19,539,000Source | 84,201,000Source | 160,652,000Source | 128,606,000Source | 119,606,000Source |
| General and Administrative ExpenseUSD | — | — | 4,871,000Source | 5,653,000Source | 6,048,000Source | 5,386,000Source | 6,743,000Source | 6,139,000Source | 21,972,000Source | 22,203,000Source | 32,412,000Source | 25,133,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | — | — | — | — | — | — | — | — | — | -86,908,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -64,923,000Source | -132,065,000Source | -88,848,000Source | -86,908,000Source |
| Investment Income, InterestUSD | — | — | 1,819,000Source | 1,991,000Source | 1,761,000Source | 2,018,000Source | 1,514,000Source | 2,166,000Source | 7,637,000Source | 7,953,000Source | — | — |
| Nonoperating Income (Expense)USD | — | — | 2,535,000Source | 2,885,000Source | 2,733,000Source | 2,979,000Source | 2,368,000Source | 2,999,000Source | 11,452,000Source | 9,867,000Source | — | — |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | 800,000Source | 900,000Source | 1,100,000Source | 1,000,000Source |
| Research and Development ExpenseUSD | — | — | 13,028,000Source | 5,956,000Source | 18,066,000Source | 11,449,000Source | 15,657,000Source | 11,584,000Source | 52,645,000Source | 33,586,000Source | 98,384,000Source | 77,813,000Source |
Offerings
Registration 333-298084
Filing attachments
tm2628355d1_ex4-1.htm · 8-K · 2026-10-27
Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT ACLARIS THERAPEUTICS, INC. Warrant Shares: Date of Issuance:, 2026 (such date, the “Issue Date”) Warrant No.: PF-[ ] THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, the registered holder hereof or its permitted assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions set forth herein, at any time on or after the Issue Date, to subscri…
Read attachment ↗acrs-ex99d1.htm · 8-K · 2026-10-27
Exhibit 99.1 Aclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4Rα Bispecific ATI-052 in Atopic Dermatitis (AD) and Asthma - Results Demonstrated Breadth and Rapidity of Response to ATI-052 in Heterogeneous Patient Populations; Pharmacodynamic Results Demonstrated Potential for Additivity/Synergy of Targeting TSLP and IL-4Rα - - Rapid and Durable Improvement in Skin and Itch Observed in Severe AD Population with ATI-052; Single Dos…
Read attachment ↗acrs-ex99d2.htm · 8-K · 2026-10-27
Exhibit 99.2 EMPOWERING PATIENTS THROUGH THERAPEUTIC INNOVATION October 27, 2026 ATI-052 Phase 1b Primary Analysis Results Atopic Dermatitis and Asthma ───────────────────────────────────── 2 Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “anticipate,” “believe,” …
Read attachment ↗tm2622183d2_ex4-2.htm · S-3ASR · 2026-08-06
Exhibit 4.2 ACLARIS THERAPEUTICS, Inc., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20__ Debt Securities Table Of Contents PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 article 2 ISSUE, DESCRIPTION, TERM…
Read attachment ↗tm2622183d2_ex4-4.htm · S-3ASR · 2026-08-06
Exhibit 4.4 Aclaris Therapeutics, Inc. and _____________, As Warrant Agent Form of Common Stock Warrant Agreement Dated As Of __________ Aclaris Therapeutics, Inc. Form of Common Stock Warrant Agreement This Common Stock Warrant Agreement (this “Agreement”), dated as of [●], between Aclaris Therapeutics, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and having a corporate trust office in […
Read attachment ↗tm2622183d2_ex4-5.htm · S-3ASR · 2026-08-06
Exhibit 4.5 Aclaris Therapeutics, Inc. and _____________, As Warrant Agent Form of Preferred Stock Warrant Agreement Dated As Of __________ Aclaris Therapeutics, Inc. Form of Preferred Stock Warrant Agreement This Preferred Stock Warrant Agreement (this “Agreement”), dated as of [●], between Aclaris Therapeutics, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and having a corporate trust of…
Read attachment ↗